top of page
CGTI.png

Angela Vollstedt, PhD MBA

Director Global Cell & Gene Therapies Portfolio Management at Novartis

I'm an accomplished Biotech & Pharma executive with deep expertise in science, product strategy and development and commercial life-cycle management. Focusing on Advanced Therapies (CAR-T and Gene Therapy), Oncology, Immunology, and Endocrinology, I've consistently led high-performing teams to achieve groundbreaking milestones in drug development and market success.

Key achievements include:

+ Driving CMC product design and development paving the way for successful market launch and life-cycle maintenance of Zarxio™, Omnitrope™, Hyrimoz™ and Tyruko™
+ Advancing ten projects to through early clinical development into late-stage development, including four successful BLA and life-cycle maintenance product improvement approvals.

As Director, Novartis Cell & Gene Therapies R&D Portfolio, I shape key assets’ direction and secure strategic partnering and funding to achieve critical regulatory milestones. My extensive experience enables me to forge strategic partnerships and accelerate product development.

I thrive in dynamic, entrepreneurial environments, where I design and launch products that transform clinical practice and improve patient outcomes. With a passion for driving innovation, I’ve recently completed my MBA to deepen my role in shaping the technology innovation space.

My commitment to excellence is rooted in servant leadership and a steadfast belief in focusing our collective efforts to make a lasting and sustainable impact on the lives of patients around the world. I am passionate about championing the next generation of leaders as a supporter of Youth Entrepreneurship and empowering Women in Advanced Therapies and beyond.

Share
  • LinkedIn
  • Youtube
  • X
  • Instagram
How we drive innovation
STORIES
MEETINGS
MEMBERS
Speakers

Uwe Gottschalk

Uwe Gottschalk is Chief Scientific Officer (CSO) at Lonza since July 2017. Between 2014 and 2017 he served as a Chief Technology Officer where he established and led the global Research and Technology organisation of Lonza Pharma/Biotech.

Jens H. Vogel, SVP & Global Head of Biotech at Bayer is an advisor of GBX EVENTS

Jesse McCool

CSO of Bionova Scientific

Jens H. Vogel, SVP & Global Head of Biotech at Bayer is an advisor of GBX EVENTS

Thomas Potgieter

SVP of Global Cell Therapy Development & Operations at Bristol Myers Squibb

Jens H. Vogel, SVP & Global Head of Biotech at Bayer is an advisor of GBX EVENTS

Paolo Martini

Chief Research & Development Officer at ReAlta Life Sciences former CSO at Moderna

Jens H. Vogel, SVP & Global Head of Biotech at Bayer is an advisor of GBX EVENTS

Gwendolyn Binder PhD

President, Science and Technology at Cabaletta Bio

Jens H. Vogel, SVP & Global Head of Biotech at Bayer is an advisor of GBX EVENTS

Warner Biddle

CEO at Kyverna Therapeutics former interim CEO at Kite a Gilead Company

Jens H. Vogel, SVP & Global Head of Biotech at Bayer is an advisor of GBX EVENTS
bottom of page